Aug. 13 Quick Takes: Qiagen shareholders opt for independence; plus IPO terms from Inhibrx, Harmony and more from Biohaven-Royalty, Scioto, Bodyport, immunoSCAPE

Qiagen to remain independent

Qiagen N.V. (NYSE:QGEN; Xetra:QIA) said it terminated its agreement to be acquired by Thermo Fisher Scientific Inc. (NYSE:TMO) after only 47% of shares were tendered by Qiagen shareholders, well below the minimum threshold of 66.7% . Thermo Fisher agreed in March to take out the molecular diagnostics company for €39 ($43.33) per share, or about $11.5 billion (see “Thermo Fisher Takes out Qiagen”)...